Literature DB >> 6470938

Plasma protein binding of warfarin: methodological considerations.

D Mungall, Y Y Wong, R L Talbert, M H Crawford, J Marshall, D W Hawkins, T M Ludden.   

Abstract

Recent theoretical work has suggested that radiochemical impurities can significantly alter the binding results for highly protein-bound drugs. We compared protein binding of warfarin by ultrafiltration and equilibrium dialysis with 98% radiochemically pure [14C]warfarin. Ultrafiltration and equilibrium dialysis were performed at 37 degrees C and pH 7.45 on the plasma of patients receiving chronic warfarin therapy. Binding to plasma from seven patients were measured in duplicate by both a nonspecific radioisotopic technique and a specific HPLC technique. The nonspecific technique gave percentage of free warfarin values of 1.84 +/- 0.11 (mean +/- SD) and 1.59 +/- 0.14 for ultrafiltration and equilibrium dialysis, respectively. The HPLC procedure yielded a percentage of free warfarin by ultrafiltration of 0.969 +/- 0.203 and a value of 0.690 +/- 0.095 by equilibrium dialysis (p less than 0.05). The HPLC procedure for protein binding was performed on plasma samples from 12 additional patients and yielded a percentage of free warfarin of 1.01 +/- 0.69 by ultrafiltration and 0.44 +/- 0.34 by equilibrium dialysis (p less than 0.05). It can be concluded that radiochemical impurities may lead to significant overestimation of the percentage of free warfarin. Ultrafiltration yielded a higher percentage of free warfarin than did equilibrium dialysis, but the ability to distinguish binding differences among patients was similar.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470938     DOI: 10.1002/jps.2600730738

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat.

Authors:  M D Levitt; J M Kneip; D G Levitt
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 2.  Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

Authors:  Damayanthi Devineni; David Polidori
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

3.  Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients.

Authors:  R F Moulds; R O Fullinfaw; R W Bury; W E Plehwe; N Jacka; K M McGrath; F I Martin
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

5.  Population pharmacokinetics of racemic warfarin in adult patients.

Authors:  D R Mungall; T M Ludden; J Marshall; D W Hawkins; R L Talbert; M H Crawford
Journal:  J Pharmacokinet Biopharm       Date:  1985-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.